SynDevRx to Present AMELIA™-1 Data at ASCO 2026 Showing Improved PI3K/AKT Class Inhibitor Responses in Breast Cancer
Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2−mBC patients with PI3K pathway alterations. May 19, 2026 /EINPresswire.com/ — SynDevRx, Inc., a clinical-stage oncology company, today announced it will share interim data from the ongoing AMELIA™-1 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The data highlights […]
SynDevRx Publishes Data On Evexomostat, Establishes New Metabo-Oncology Treatment Modality
Feb. 20, 2026: SynDevRx today announced the publication of a seminal research article in Frontiers in Oncology detailing the anti-tumor and systemic metabolic improvements of its lead investigational therapy, evexomostat in pre-clinical models of obesity-accelerated cancer.
Aretha-1 Initial Efficacy and Safety Data in mTNBC Patients To Be Presented at SABCS
Safety Run-in Cohort Results Show Anti-tumor Activity Plus Systemic Metabolic Improvements with Evexomostat Plus Eribulin in Late-line Metastatic TNBC Patients to be Presented at SABCS 2025
Evexomostat Phase 1 Clinical Safety Study in Late-Stage Cancer Patients
2025 Cornelius A phase 1 safety study of evexomostat in patients with late-stage cancer
$1.2M Grant Awarded for Groundbreaking Prostate Cancer Research on SynDevRx MetAP2 Inhibitor ‘Evexomostat’
Cambridge, MA (USA) and Brisbane (Australia) – Queensland University of Technology (QUT) in Brisbane, Australia, together with SynDevRx, Inc., a leader in polymer-drug conjugates for cancer and for metabolic dysfunction are honored to announce the receipt of a $1.2 million grant from the US Department of Defense (DoD) for continued research on evexomostat, SynDevRx’s novel […]
AACR Journal MCT Publishes Initial Disclosure Article on Evexomostat/SDX-7320
Pharmacological Characterization of SDX-7320/Evexomostat: a Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-Tumor and Anti-Metastatic Activity Methionine aminopeptidase type 2 (MetAP2) is a ubiquitous, evolutionarily conserved metalloprotease fundamental to protein biosynthesis which catalyzes removal of the N-terminal methionine residue from nascent polypeptides. MetAP2 is an attractive target for cancer therapeutics based upon its over-expression in […]
Amelia-1 Clinical Trial Fully Open To Recruitment, 1st Patient Data on Combination Study with PI3K Inhibitor and SERD
SynDevRx, Inc. today announced the opening of the Amelia-1 study and data from the first patient treated in its Phase 1b/2 clinical study testing the novel MetAP2 inhibitor evexomostat (aka SDX-7320) in combination with the PI3K inhibitor alpelisib (Piqray®) and the estrogen receptor degrader (SERD) drug fulvestrant (Faslodex®) in breast cancer patients with metastatic disease […]
New Experimental Treatment for Prostate Cancer Revealed at AACR
SDX AACR 2023 poster 05Apr 2023.pptx PRESS RELEASE • APR 14, 2023 08:00 EDT Evexomostat (SDX-7320) shows potent anti-tumor effects in pre-clinical models of prostate cancer, including castration-resistant. New research data to be presented at AACR 2023 in Orlando, FL
SynDevRx Joins ‘Touch – The Black Breast Cancer Alliance’ CEO Ricki Fairley in Metabo-Oncology Podcast – Wed. Oct 5, 2022 at 6:00 PM
Aug. 31, 2022 – SynDevRx Presents Scientific Poster on Anti-Fibrosis Data with Evexomostat at the 2022 IPF Conference in Boston
Aug. 31, 2022 – SynDevRx, Inc., a clinical-stage biotechnology company leading the development of treatments for obesity-accelerated cancers, today announced the presentation of new scientific data on its lead compound evexomostat (SDX-7320) in a series of fibrosis models demonstrating potent anti-fibrosis data monotherapy and in combination with the standard of care therapy nintedanib. Evexomostat significantly […]